APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition

Rémi Buisson1, Michael S Lawrence1,2, Cyril H Benes1

  • 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.

Cancer Research
|July 13, 2017
PubMed

Insights

Apolipoprotein B mRNA editing enzyme (APOBEC3A/3B) causes replication stress by creating abasic sites. APOBEC3A-expressing cells are sensitive to ATR inhibitors, leading to replication catastrophe and potential new cancer therapies.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Genetics

Background:

  • APOBEC3A and APOBEC3B are key drivers of mutations in cancer.
  • Their activity can lead to unique replication stress by inducing abasic sites.

Purpose of the Study:

  • To investigate the mechanism of APOBEC3A/3B-induced replication stress.
  • To determine the selective sensitivity of APOBEC3A-expressing cells to ATR inhibitors.

Main Methods:

  • Assessing APOBEC3A/3B activity in cancer cell lines.
  • Treating cells with ATR inhibitors and various DNA replication inhibitors.
  • Analyzing replication fork dynamics and DNA damage accumulation.

Main Results:

  • APOBEC3A/3B activity induces abasic sites at replication forks, causing replication stress.
  • APOBEC3A-expressing cells show selective sensitivity to ATR inhibitors.
  • ATR inhibition triggers a feedback loop, leading to replication catastrophe in APOBEC3A/3B-high cells.

Conclusions:

  • APOBEC3A/3B-driven replication stress defines a new mechanism in cancer.
  • This mechanism confers susceptibility to ATR inhibitors, suggesting a therapeutic vulnerability.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K